We are live on ! Find out more
FULC icon

Fulcrum Therapeutics
FULC

101 hedge funds and large institutions have $421M invested in Fulcrum Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

469% more call options, than puts

Call options by funds: $4.61M | Put options by funds: $811K

182% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 11

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

68% more capital invested

Capital invested by funds: $250M → $421M (+$170M)

25% more funds holding

Funds holding: 81 → 101 (+20)

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

9.56% more ownership

Funds ownership: 91.22% → 100.78% (+9.6%)

Holders
101
Holders Change
+20
Holders Change %
+24.69%
% of All Funds
1.47%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
31
Increased
24
Reduced
21
Closed
11
Calls
$4.61M
Puts
$811K
Net Calls
+$3.8M
Net Calls Change
+$1.94M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.77M
2
LGM
Logos Global Management
California
+$5.32M
3
Deutsche Bank
Deutsche Bank
Germany
+$3.65M
4
Goldman Sachs
Goldman Sachs
New York
+$2.72M
5
Invesco
Invesco
Georgia
+$2.11M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.99M
2
CAC
Cowen and Company
New York
-$3.7M
3
Millennium Management
Millennium Management
New York
-$2.52M
4
Marshall Wace
Marshall Wace
United Kingdom
-$2.41M
5
VC
Vivo Capital
California
-$2.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$3.35M -$114K -25,800 -5%
Invesco
27
Invesco
Georgia
$3.21M +$2.11M +476,206 New
Millennium Management
28
Millennium Management
New York
$2.95M -$2.52M -567,179 -56%
SSA
29
Schonfeld Strategic Advisors
New York
$2.92M +$1.92M +432,533 New
SC
30
Stempoint Capital
New York
$2.54M +$1.67M +376,573 New
Jane Street
31
Jane Street
New York
$2.34M +$1.37M +308,349 +801%
Bessemer Group
32
Bessemer Group
New Jersey
$1.94M – – –
Citigroup
33
Citigroup
New York
$1.93M +$870K +196,109 +220%
Two Sigma Investments
34
Two Sigma Investments
New York
$1.77M -$1.33M -300,371 -53%
Aberdeen Group
35
Aberdeen Group
United Kingdom
$1.73M +$1.14M +256,888 New
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$1.64M +$1.02M +229,842 +1,759%
AllianceBernstein
37
AllianceBernstein
Tennessee
$1.62M +$26.3K +5,920 +3%
Alyeska Investment Group
38
Alyeska Investment Group
Illinois
$1.36M – – –
Bank of America
39
Bank of America
North Carolina
$1.27M +$215K +48,428 +35%
State Street
40
State Street
Massachusetts
$1.24M – – –
SPS
41
Susquehanna Portfolio Strategies
Pennsylvania
$1.14M +$749K +168,775 New
Northern Trust
42
Northern Trust
Illinois
$979K +$8.8K +1,984 +1%
LCM
43
Laurion Capital Management
New York
$977K +$642K +144,721 New
RC
44
RBF Capital
California
$945K -$62.6K -14,100 -9%
FT
45
Fiduciary Trust
Massachusetts
$922K – – –
AI
46
Acuitas Investments
Washington
$910K +$173 +39 +0%
OM
47
Opaleye Management
Massachusetts
$878K +$577K +130,000 New
BCM
48
Bridgeway Capital Management
Texas
$854K – – –
AAA
49
Affinity Asset Advisors
New York
$844K +$555K +125,000 New
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
$824K -$636K -143,376 -54%
1
2
3 4 5

FULC Hedge Fund Activity: Q4 2023 in Review

101 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q4 2023, worth a combined $421M — up 68% from $250M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new FULC positions and 11 closed out — a net gain of 20 holders — while 24 added to existing stakes and 21 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $6.77M. The largest seller was Adage Capital Partners, cutting an estimated $3.99M.

  • 101 institutional investors held Fulcrum Therapeutics (FULC) as of Q4 2023, up from 81 in Q3 2023.
  • Funds reported $421M of Fulcrum Therapeutics stock for Q4 2023, up 68% quarter-over-quarter.
  • 31 funds opened new Fulcrum Therapeutics positions in Q4 2023 and 11 closed out, a net change of +20 holders.
  • The largest Fulcrum Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $6.77M added.
  • The largest Fulcrum Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $3.99M sold.

Based on aggregated 13F filings for Q4 2023.